Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co‐morbid depressive disorder: a randomized, double‐blind study

Altıntoprak, Ayşe Ender; Zorlu, Nabi; Çoşkunol, Hakan; Akdeniz, Fisun; Kitapçıoğlu, Gül

doi:10.1002/hup.935

Cited by 38 publications

(24 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The significant within-group decrease in depressive symptoms noted during the course of the current treatment trial is consistent with the within-group finding of an open label study by Yoon and colleagues (2006) conducted in South Korea and the between-group findings of a double-blind study by Altintoprak and colleagues (2008) conducted in Turkey. Both of those studies reported significant decreases in depressive symptoms in their studies of comorbid subjects involving mirtazapine.…”

Section: Discussionsupporting

confidence: 87%

Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial

Cornelius

Chung

Douaihy

et al. 2016

Psychiatry Research

View full text Add to dashboard Cite

This was a first double-blind, placebo-controlled pilot study to evaluate the efficacy of the novel antidepressant medication mirtazapine for treating both the depressive symptoms and the level of alcohol consumption of subjects with comorbid major depressive disorder and an alcohol use disorder (MDD/AUD). The results of two previous studies of mirtazapine in MDD/AUD subjects had suggested efficacy for mirtazapine for decreasing their level of depressive symptoms, but level of alcohol consumption had not been assessed in those studies. All subjects in this 12-week pilot study were randomized to either mirtazapine or placebo, and also received motivational enhancement therapy. Between-group analyses involving the outcome measures of depressive symptoms, level of alcohol consumption, and level of alcohol craving indicated no significant differences between groups, possibly because of limited sample size. However, within-group t tests in the mirtazapine group showed a significant decrease in depressive symptoms by week 2, also noted at all subsequent assessments (weeks 3, 4, 6, 8, 10, and 12) during the 12-week study. In contrast, no significant decrease in depressive symptoms was noted in the placebo group until week 8. No evidence of efficacy was found for mirtazapine for decreasing level of alcohol consumption in MDD /AUD subjects.

show abstract

Section: Discussionsupporting

confidence: 87%

Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial

Cornelius

Chung

Douaihy

et al. 2016

Psychiatry Research

View full text Add to dashboard Cite

show abstract

“…We are currently using plasma levels of catecholamine metabolites to determine which antidepressant drug should be used to treat depressive patients with alcohol dependence. In a randomized double-blind study, Altintoprak et al (2008) recently found that mirtazapine is effective and well tolerated in alcoholic patients with comorbid depressive disorders. Muhonen et al (2008) reported the efficacy of memantine, a noncompetitive glutamate N-methyl-D-aspartate receptor blocker, for major depressive disorders comorbid with alcohol dependence.…”

Section: Discussionmentioning

confidence: 98%

Serum levels of brain‐derived neurotrophic factor in comorbidity of depression and alcohol dependence

Umene-Nakano

Yoshimura

Ikenouchi-Sugita

et al. 2009

Human Psychopharmacology

View full text Add to dashboard Cite

Alcohol dependence is often comorbid with depression. The purpose of the present study was to compare serum brain-derived neurotrophic factor (BDNF) levels between depressive patients with and without alcohol dependence. Our subjects were 16 inpatients (M/F: 13/3, age: 48 +/- 8 years) at our university hospital who met the DSM-IV-TR criteria for both major depressive disorder and alcohol dependence and whose Hamilton Rating Scale for Depression (HAM-D) scores were at least 15. Twenty sex- and age-matched depressive patients and 20 healthy subjects were also examined. Serum BDNF levels in the depressive patients with (9.0 +/- 4.3 ng/ml) and without (9.8 +/- 5.2 ng/ml) alcohol dependence were significantly lower than those in the healthy subjects (21.1 +/- 7.0 ng/ml); however, no significant difference was found in the serum BDNF levels of depressive patients with and without alcohol dependence. Eight of the 16 (50%) depressive patients suffering from both depression and alcohol dependence responded to 8 weeks of treatment with antidepressant drugs which significantly increased their serum BDNF levels. These results suggest that the serum BDNF level is a useful biological marker for depression in patients with alcohol dependence.

show abstract

“…High heterogeneity (Q=14.05, df=2, p<.001, I 2 =86%) persisted in the low baseline depression severity studies (n=3). Nine studies reported depression scores at multiple follow-up timepoints (Altintoprak, et al, 2008;R. A.…”

Section: Change In Depression During Treatmentmentioning

confidence: 99%

“…Follow-up completion rates in these studies ranged from 48 to 93% (median 70%). The remaining 6 studies (Altintoprak et al, 2008;Dorus et al, 1989;Janiri et al, 1996;Mason et al, 1996;Paparrigopoulos et al, 2010;Petrakis et al, 2007) were excluded from the meta-analysis because their reported outcomes were not clearly identified as relating to the intention-to-treat sample.…”

Section: Insert Table 1 About Herementioning

confidence: 99%

Depression in patients with alcohol use disorders: Systematic review and meta-analysis of outcomes for independent and substance-induced disorders

Foulds

Adamson

Boden

et al. 2015

Journal of Affective Disorders

117

View full text Add to dashboard Cite

Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co‐morbid depressive disorder: a randomized, double‐blind study

Abstract: The treatment with either mirtazapine or amitriptyline resulted with the reduction of HDRS and craving scores. The side-effect profile of mirtazapine was relatively favorable in our study.

Cited by 38 publications

References 33 publications

Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial

Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial

Serum levels of brain‐derived neurotrophic factor in comorbidity of depression and alcohol dependence

Depression in patients with alcohol use disorders: Systematic review and meta-analysis of outcomes for independent and substance-induced disorders

Contact Info

Product

Resources

About